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Poster Session II S321failures while still adhering to the transition timeline. Clinician as-
sessment of the FMEA process using a 5-point Likert scale found
that participants felt the ‘rapid-cycle’ model was effective and effi-
cient. Post-transition assessment of patient engraftment, graft fail-
ure, and safety event reports provide initial confirmation that
product and patient safety were maintained during this
transition.Traditional vs. ‘‘Rapid-cycle’’ FMEA
Traditional FMEA ‘‘Rapid-cycle’’ FMEA
Purpose A systems-oriented, prospective approach that
identifies potential process fail-points, assesses
their level of risk, and helps prioritizes response
with the goal of reducing error occurrence
and/or mitigating harm
Facilitator
responsibilities
Coordinate
FMEA meetings -
provide expertise
and accountability.
Coordinate FMEA.
Prepare initial process
flows. Begin failpoint
identification.
Calculate risk
priority numbers and
categorize
failure modes
(high, moderate or
low severity).
Group member
(Clinician)
responsibilities
Perform process
mapping. Identify and
score failure modes.
Calculate risk priority
numbers and categorize
failure modes
(high, moderate
or low severity).
Identify corrective
actions.
Focus on failure
mode
identification,
scoring and
correction.
Meeting
requirements
6-12 2
Timeline 4-12 months 2-4 months446
A HEMATOPOIETIC STEM CELL TRANSPLANT QUALITY, CLINICAL,
CELLULAR DASHBOARD: WHAT IS THE EVIDENCE?
Cartwright, F., Andersen, S., Cervone, K.K., Feldman, T., Mendez, S.
New York University Langone Medical Center, New York, NY
Identifying HSCT clinical, quality, cellular indicators with valid
benchmarks is essential to evaluate quality of care and provides di-
rection for program management and growth (strategic planning).
Indicators and benchmarks are selected based on level of evidence
(clinical trial results, survey reports, international and national re-
search data bases), best practices among centers, and institutional
reports. This paper describes the process that an academic institu-
tion used to develop and mainatin an up-to-date HSCT clinical,
quality, cellular dashboard. Using a reveiw of the above literature,
HSCT indicators were evaluated based on the following five cat-
egories: 1) level of priority (relevance), 2) established benchmarks,
3) relationship between process and outcomes, 4) measurable with
numerator and denominator, and 5) ease of data collection. To ex-
plore how variations in institutional and administrative infrastruc-
ture, patient population served, and practice and treatment
patterns influences outcomes and establishment of benchmarks,
a critique of the literature that examined the following indicators
was conducted: microbial contamination of product, blood stream
infections, time to engraftment, ICU admissions, length of stay,
mortality, grade 3 – 4 toxicities. The dashboard guides the Quality
& Performance Improvement Agenda. Opportunities for improve-
ment are identified.447
CRITICAL COMPONENTS OF PATIENT SATISFACTION IN LARGE STEM
CELL TRANSPLANT OUTPATIENT CLINIC
Adornetto-Garcia, D.L., Sorensen, S.H., Stevens, C. UT M.D. Anderson
Cancer Center, Houston, TX
Measuring patient satisfaction in the outpatient clinic of one of
the largest stem cell transplant centers in the country is important
to ongoing improvement of the program. It is also a key activity
of clinical administrative staff in their quest to improve clinic func-
tions. Nursing leaders in the Stem Cell Transplant Outpatient
Clinic identified and measured three targeted patient satisfaction
areas, and based on their findings, implemented changes. The focus
areas included phone communication, continuity of care, and ‘‘wait
times’’. A patient survey process and questions were developed. Sur-
vey questions included items about ease of contacting clinic staff,
how long they were placed on hold, and if staff returned calls. Pa-
tients were asked if they knew their team, were informed of tests,
and received consistent information. They were also surveyed about
length of wait times and time from arrival to seeing their physician,
perceptions of acceptable wait times and whether they were kept in-
formed. Over 100 patients have been surveyed at 6-month intervals
with return rates exceeding 80%. Based on survey findings in these
areas, improvements were made including installation of a new
phone system, voicemail guidelines, a team member sheet, and revi-
sion of education materials. Measurement and evaluation of patient
satisfaction continues to be an important role for the SCT leaders.
Utilizing the survey process, the team is able to review results and
implement action plans for improvement. Staff involvement has
been key to the success of this process. Discussion of results, action
plans, and outcomes are done at staff meetings. Continual follow-up
and evaluation are necessary to assure improvements are sustained.
The findings and improvements made by the SCT leadership team
may be useful to other nurse leaders and staff in their efforts to im-
prove patient satisfaction, a key component to the success of the
SCT journey.TRANSPLANT NURSING: RESEARCH448
COLONIZATION OF TOTAL PARENTERAL NUTRITION ADMINISTRATION
SETS IN IMMUNOCOMPROMISED CHILDREN
Norville, R.1, Lee, D.1, Hyde, A.1, Horvath, B.1, Marilyn, H.2 1Texas
Children’s Hospital, Houston, TX; 2Texas Children’s Hospital, Houston,
TX; 3Texas Children’s Hospital, Houston, TX; 4Texas Children’s Hospital,
Houston, TX; 5Baylor College of Medicine, Houston, TX
Purpose: To determine the incidence of bacterial and yeast colo-
nization in total parenteral nutrition (TPN) fluid administration
sets in immunocompromised children and to explore the inci-
dence of infusate-related bloodstream infection (BSI) in this
group of patients.
Background: Routine replacement of IV administration sets has
been advocated to prevent infectious complications of IV therapy
(deMoissac, 1998). Research studies to date provide no data for in-
fusate-related BSI that compares administration set changes at in-
tervals of 72 hours and 96 hours among patients receiving TPN
(Gillies, 2004).
Sample and Methods: The sample included 14 immunocompro-
mised children who were receiving TPN. Five infusate fluid samples
were collected from each patient for a total of 69 samples. Qualitative
cultures of the TPN fluid were obtained to determine the incidence
of colonization with bacteria and yeast. A 1 ml sample of TPN fluid
was obtained at times 0, 24, 48, 72 and 96 hours after a new TPN ad-
ministration set change. Specimens were obtained from the injection
port immediately above the filter. TPN fluid bags were changed ev-
ery 24 hours.
Results: Twelve bone marrow transplant patients and two oncol-
ogy patients with double lumen central lines participated in the
study. None of the TPN infusate fluid samples were colonized
with bacteria or yeast at any of the data collection time points.
S322 Poster Session IITwo patients had a positive blood culture during the study time pe-
riod; however, the blood cultures were not associated with the
TPN fluid or administration set since all fluid samples remained
negative for bacteria or yeast.
Implications for Nursing: This study was the first to describe no
occurrence of TPN infusate colonization over time in immunocom-
promised children. Findings from this study support the current
practice for TPN tubing administration set change at the study insti-
tution.449
A QUALITATIVE AND OBSERVATIONAL STUDY OF POST-MODERN
PARENTAL ROLES DURING THE CHILD’S HAEMATOPOIETIC STEM CELL
TRANSPLANTATION (HSCT) TREATMENT
Larsen, H.B.1,4,5, Heilmann, C.J.2, Johansen, C.3, Adamsen, L.4 1Rigsho-
spitalet, Copenhagen, Denmark; 2Rigshospitalet, Copenhagen, Denmark;
3Cancer Society Danish, Copenhagen, Denmark; 4The University Hospi-
tals Centre for Nursing and Care Research, Copenhagen, Denmark; 5Uni-
versity of Copenhagen, Denmark
Purpose: Parents to children undergoing treatment with allogeneic
HSCT in protective isolation, experience distress related to the
child’s care. Parents struggle to cope with the stress related to
the child’s disease; this includes anxiety related to survival poten-
tial, side effects, treatment complications and the child’s reaction
to the hospitalisation. The aim of this study was to investigate
the parents’ experiences and reflections about their role in caring
for their child.
Materials and methods: Sixteen interviews with parents were
held using convenient sampling and based on the availability
of parents in the outpatient clinic. The interviews were analysed
using a theoretical ideal type construction inspired by Max We-
ber and an interactionistic approach inspired by Arlie Hochs-
child.
Results: Three types of approaches emerged 1) expertise-minded,
2) dialogue-minded and 3) socially challenged parents. Expertise-
minded parents base their care and interactions on medical knowl-
edge. To dialogue parents it’s important that emotions are incorpo-
rated in the rationale for care. When expertise-minded and
dialogue-minded parents experience that their approaches to care
are not meet, conflicts arise with the child, between the parents
or with the medical staff. Being able to manage the expertise-
minded or the dialogue-minded approaches requires emotional
work in the form of both surface- and deep acting (to induce or
suppress feelings in order to sustain outward countenance that co-
axes an appropriate state of mind in others) by the parents. Socially
challenged parents fail to adopt either of the two above-mentioned
approaches and often fail to manage the required emotional work.
Socially challenged parents are performing to the best of their abil-
ities but experience conflicts and distress in the care related to their
child.
Conclusion:The three described types of approach may provide
a new perspective on the interactions that occur between par-
ents, child and staff during treatment with HSCT. Better un-Oral Functioning Impairment
SWALLOWING
4-point Likert Scale No Crotherapy (%) Cryotherapy (%) No Crothe
Not At All 12 (60) 12 (60) 11 (5
A Little Bit 3 (15) 6 (30) 4 (2
Quite A Bit 2 (10) 2 (10) 2 (1
Very Much 3 (15) 0 (0) 3 (1
Max value per patient Study Days 0-14.derstanding these complex interactions may potentially
diminish parents and children’s levels of distress. Furthermore,
understanding of the interactions help medical staff to identify
socially challenge parents and provide parents with the assis-
tance and guidance they need to manage the care for their
child.450
EFFECT OF ORAL CROTHERAPY ON MUCOSITIS-RELATED PAIN AND
PATIENT FUNCTIONING IN HEMATOPOEITIC STEM CELL TRANSPLANT
RECIPIENTS RECEIVING HIGH-DOSE MELPHALAN
Robenolt, J.1, Trovato, J.1, Thompson, J.1, Gordon, S.2, de Vera, M.3
1University of Maryland Medical Center, Baltimore, MD; 2Univesity of
Maryland Dental School, Baltimore, MD; 3University of Maryland Med-
ical Center, Baltimore, MD
Purpose:Cryotherapy is recommended as prophylaxis for muco-
sitis in the Multinational Association of Supportive Care in Can-
cer (MASCC) guidelines (Level II evidence, grade A
recommendation), for patients receiving high-dose melphalan.
This is a randomized, prospective study investigating the effects
of oral cryotherapy in patients who are receiving melphalan
doses $140 mg/m2, either alone or as part of the BEAM regi-
men followed by autologous hematopoietic stem cell transplant
(HSCT).
Methods: This study is approved by the Institutional Review
Board at the University of Maryland Marlene and Stewart Green-
ebaum Cancer Center. The goal is to enroll 40 adult patients 18
years of age or older undergoing high-dose melphalan treatment
alone or as part of the BEAM regimen followed by autologous
HSCT. Subjects meeting the eligibility criteria, following in-
formed consent, will be randomized to receive cryotherapy or no
cryotherapy (1:1 ratio). Cryotherapy will be administered five min-
utes prior to the initiation of high-dose melphalan, during the in-
fusion, and for thirty minutes post infusion. The primary objective
of this study is to collect and compare the intensity of mucositis-
related pain in HSCT patients receiving high-dose melphalan or
BEAM chemotherapy with or without oral cryotherapy for 14
days. The secondary objectives include measuring patient func-
tioning (swallowing, eating, and talking); documenting the grade
of mucositis; and documenting complications related to oral cryo-
therapy.
Result/Conclusion: Cryotherapy group reported significantly less
mucositis related pain ‘‘Right Now’’ (p5 0.027) and over ‘‘Past 24
Hours’’ (p5 0.033) beginning on study day 8 continuing through
study day 14. No subjects in the cryotherapy group reported oral
functioning (swallowing, talking, eating) as ‘‘Very Much’’ impaired.
No subjects in either group developed grade 3/4 oral mucositis based
on WHO Oral Mucositis Scale. Administration of oral cryotherapy
was well tolerated.
Limitations: Variability of PPFQ and/or cryotherapy administra-
tion.
Future directions: Examine risk factors for development of oral
mucositis such as mg/kg dose exposure, gender, and renal
function.EATING TALKING
rapy (%) Crotherapy (%) No Crotherapy (%) Crotherapy (%)
5) 15 (75) 13 (65) 17 (85)
0) 3 (15) 0 (0) 1 (5)
0) 2 (10) 4 (20) 2 (10)
5) 0 (0) 3 (15) 0 (0)
